Cytokinetics, Incorporated filings document a specialty cardiovascular biopharmaceutical company with common stock listed on the Nasdaq Global Select Market. Its 8-K reports cover financial results, corporate presentations, MYQORZO® regulatory approvals, clinical and regulatory disclosures, and material capital-structure events such as underwriting agreements for common stock offerings.
Proxy materials describe board elections, executive compensation, auditor ratification and equity plan amendments, including matters tied to the company’s employee stock purchase plan. Other filings address governance changes, risk disclosures, registered securities, exhibits and Inline XBRL cover-page data associated with Cytokinetics’ public-company reporting obligations.
The Vanguard Group filed Amendment No. 11 to a Schedule 13G/A for Cytokinetics Inc. The amendment states that, following an internal realignment described in the filing, The Vanguard Group reports 0 shares beneficially owned of Cytokinetics Common Stock, representing 0% of the class as shown in the filing dated 03/13/2026 with a signature on 03/26/2026. The filing explains certain subsidiaries and business divisions will report ownership separately in reliance on SEC Release No. 34-39538.
Cytokinetics EVP and CFO Sung Lee reported an open-market sale of 4,935 shares of Common Stock at $62.15 per share. According to the footnote, this was a company-compelled sell-to-cover transaction to satisfy tax withholding obligations from RSU vesting, rather than a discretionary sale. After the transaction, Lee directly holds 87,127 shares, indicating he retains a substantial equity position.
Cytokinetics EVP and Chief Commercial Officer Andrew Callos reported a company‑compelled sale of 8,542 shares of Common Stock at $62.15 per share on March 17, 2026 to cover tax withholding from RSU vesting.
These sell‑to‑cover transactions were executed in two tranches and are tied to compensation, rather than discretionary trading. Following the sales, Callos directly holds 71,573 Cytokinetics shares, maintaining a substantial equity stake in the company.
CYTOKINETICS INC EVP of R&D Fady Malik reported tax-related stock sales. On the reported date, he sold a total of 12,033 shares of common stock in open-market transactions at $62.15 per share.
Footnotes state these were company-compelled sell-to-cover transactions to satisfy tax withholding obligations from RSU vesting, indicating they were driven by taxes rather than discretionary selling. After the transactions, he continued to hold 153,902 shares directly.
Cytokinetics Inc. President & CEO Robert I. Blum reported an open-market sale of 36,601 shares of common stock at $62.15 per share. According to the footnotes, these were company-compelled sell-to-cover transactions to satisfy tax withholding obligations from RSU vesting, rather than discretionary sales.
After these transactions, Blum holds 430,330 shares of common stock directly. In addition, 2,083 shares are held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares are held by The Brittany Blum 2003 Irrevocable Trust as indirect holdings.
Cytokinetics EVP and Chief Commercial Officer Andrew Callos sold 1,930 shares of Common Stock in an open-market transaction at $62.07 per share. The sale was reported as a direct ownership transaction. After this trade, Callos continues to hold 78,185 shares of Cytokinetics common stock.
Morgan Stanley Smith Barney LLC filed a Form 144 disclosing resale notices for Common stock related to multiple 10b5-1 sales attributed to Andrew Callos. The filing lists dated sales and per‑trade quantities with associated cash amounts, including 03/05/2026 sales of 15,000 and 11,000 shares.
Cytokinetics President & CEO Robert I. Blum reported equity awards and updated holdings. On March 15, 2026, he received an annual grant of 75,258 shares of common stock as restricted stock units that convert 1:1 into common shares.
These RSUs vest 40% on the first anniversary of the grant date, another 40% on the second anniversary, and the remaining 20% on the third, subject to continued employment under the company’s Amended and Restated 2004 Equity Incentive Plan. He was also granted 1,665 incentive stock options and 111,864 non-qualified stock options at an exercise price of $60.06 per share, vesting in 48 equal monthly installments and expiring on March 14, 2036. Following these awards, his direct common stock holdings total 466,931 shares. Indirectly, 2,083 shares are held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares by The Brittany Blum 2003 Irrevocable Trust.
Cytokinetics executive Andrew Callos received new equity awards as part of his compensation. On March 15, 2026, he was granted 1,665 incentive stock options and 29,480 non-qualified stock options to buy common stock at an exercise price of $60.06 per share, expiring on March 14, 2036.
These stock options vest in 48 equal monthly installments, subject to his continued employment and the company’s Amended and Restated 2004 Equity Incentive Plan. He also received 20,646 restricted stock units as an annual equity award and 13,320 restricted stock units as a special supplemental award, which convert 1:1 into common shares as they vest over one to three years.
Following these awards, Callos directly holds 81,824 shares of common stock. All transactions are coded as awards or acquisitions, with no open-market purchases or sales reported in this filing.
Cytokinetics Inc. reported that Chief Legal & Admin Officer Jeffrey Hessekiel received new equity awards. On March 15, 2026, he was granted 8,325 incentive stock options and 22,820 non-qualified stock options, each with an exercise price of $60.06 per share and expiring on March 14, 2036. These stock options vest in 48 equal monthly installments, conditioned on his continued employment under the company’s Amended and Restated 2004 Equity Incentive Plan. He also received an annual equity award of 20,646 shares of common stock in the form of restricted stock units that convert 1-for-1 into common shares and vest 40% on each of the first and second anniversaries of the grant date and 20% on the third anniversary, also subject to continued employment. Following these awards, he directly holds 107,943 shares of Cytokinetics common stock.